Abstract

Prameha (Diabetes mellitus) is an age long disease known from vedic period and now it is a leading lifestyle disorder. Diabetes mellitus is a group of metabolic syndromes of fat, protein and carbohydrate which is due to absolute or relative deficiency of insulin, characterized by hyperglycemia over a prolonged period with polyuria, polydipsia, and polyphagia like symptoms. The estimates in 2019 showed that 77 million individuals had diabetes in India, which is expected to rise to over 134 million by 2045. It has turned out to be the biggest “silent killer” in today’s world. This is an Open label Comparative clinical study with pre-test and post-test design where in 60 patients suffering from Prameha (type 2 DM) of either gender between the age group of 25 to 75 years were randomly selected and grouped into Group A and Group B. The 30 patients in Group A were treated with Arogyavardhini vati & Madhusudhan vati with Metformin (500 mg) and Glimepiride (1mg) BD. Group B of 30 patients were given Metformin (500mg) and Glimepiride (1 mg) for 120 days. Results obtained in subjective and objective parameters were analyzed for the statistical significance by adapting paired T test, unpaired T test, Mann-Whitney Z and Wilcoxon Signed Ranks Test Z. The study revealed that Group A was found to be more effective in bringing symptomatic relief and improving biochemical markers in the patients of Prameha.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call